ArcticZymes Technologies ASA

Equities

AZT

NO0010014632

Biotechnology & Medical Research

Market Closed - Oslo Bors 10:45:00 2024-04-29 am EDT 5-day change 1st Jan Change
25.9 NOK -0.38% Intraday chart for ArcticZymes Technologies ASA -0.96% -38.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Norway's ArcticZymes Teams Up With Austrian Group for Bionanoparticles Research Project MT
ArcticZymes Technologies ASA Initiates Joint Research Project with Austrian Centre of Industrial Biotechnology CI
ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board Member CI
ArcticZymes Technologies ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
ArcticZymes Technologies ASA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : ArcticZymes Technologies ASA, Q4 2023 Earnings Call, Feb 01, 2024
Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San Hq CI
Norway’s ArcticZymes Technologies Manufactures GMP-grade Enzyme MT
ArcticZymes Technologies ASA Launches T7 RNA Polymerase CI
ArcticZymes Technologies ASA Enters into an Agreement with Biomatter CI
ArcticZymes Technologies ASA Announces Partnership with Biomatter CI
ArcticZymes Technologies ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : ArcticZymes Technologies ASA, Q3 2023 Earnings Call, Nov 02, 2023
ArcticZymes Technologies' Wins US FDA's Filing Type 2 Status for Enzyme MT
ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA CI
ArcticZymes Technologies ASA(OB:AZT) dropped from S&P Global BMI Index CI
Transcript : ArcticZymes Technologies ASA, Q2 2023 Earnings Call, Aug 17, 2023
ArcticZymes Technologies ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
ArcticZymes Technologies ASA Launches Taq?? DNA Polymerase CI
ArcticZymes Technologies Appoints New CEO MT
ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023 CI
ArcticZymes Technologies Files DMF for SAN HQ GMP CI
Transcript : ArcticZymes Technologies ASA, Q1 2023 Earnings Call, May 04, 2023
ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart ArcticZymes Technologies ASA
More charts
Arcticzymes Technologies ASA is a Norway-based holding company providing support functions to the ArcticZymes AS subsidiary including distribution, administration, finance, Information Technology (IT) and quality assurance. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Company’s enzymes include cold activeness and salt tolerance. The Company’s divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
26 NOK
Average target price
32 NOK
Spread / Average Target
+23.08%
Consensus
  1. Stock Market
  2. Equities
  3. AZT Stock
  4. News ArcticZymes Technologies ASA
  5. Norway’s ArcticZymes Technologies Manufactures GMP-grade Enzyme